Nicotine Metabolism and Bladder Cancer: A New Prognostic Signature
Author Information
Author(s): Zhan Yating, Weng Min, Guo Yangyang, Lv Dingfeng, Zhao Feng, Yan Zejun, Jiang Junhui, Xiao Yanyi, Yao Lili
Primary Institution: The First Affiliated Hospital of Ningbo University
Hypothesis
The study aims to identify and validate a nicotine metabolism-related signature for bladder cancer using bioinformatics and machine learning.
Conclusion
The nicotine metabolism-related signature may provide valuable insights into clinical prognosis and potential benefits of immunotherapy in bladder cancer patients.
Supporting Evidence
- The study identified three nicotine metabolism-related clusters with distinct prognostic outcomes.
- A four-gene signature was developed that showed high accuracy in predicting patient outcomes.
- Patients with low NRS scores had better overall survival compared to those with high NRS scores.
- The NRS was validated across multiple independent cohorts, demonstrating its robustness.
- High NRS scores correlated with increased immune checkpoint expression, indicating potential immunotherapy resistance.
Takeaway
This study found a new way to predict how bladder cancer patients will do based on how their bodies process nicotine, which could help doctors choose better treatments.
Methodology
The study used bioinformatics to analyze nicotine metabolism-related genes and machine learning to develop a prognostic signature.
Limitations
The study relies on public databases for validation and lacks in vivo experiments to explore the mechanisms of MKRN1 in bladder cancer.
Participant Demographics
The study included bladder cancer patients from TCGA and GEO databases, with a focus on various clinical characteristics.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website